GlaxoSmithKlineE Valuation

Is BIOC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIOC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BIOC (EGP31.31) is trading above our estimate of fair value (EGP2.44)

Significantly Below Fair Value: BIOC is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIOC?

Other financial metrics that can be useful for relative valuation.

BIOC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.9x
Enterprise Value/EBITDA4.2x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does BIOC's PE Ratio compare to its peers?

The above table shows the PE ratio for BIOC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average10.2x
MIPH MINAPHARM Pharmaceuticals
5.8xn/aج.م2.7b
RMDA Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E
19.1x27.1%ج.م4.2b
AXPH Alexandria For Pharmaceuticals & Chemical Industries
7.7xn/aج.م1.2b
OCPH October PharmaE
8xn/aج.م1.2b
BIOC GlaxoSmithKlineE
35.3xn/aج.م2.7b

Price-To-Earnings vs Peers: BIOC is expensive based on its Price-To-Earnings Ratio (35.3x) compared to the peer average (10.2x).


Price to Earnings Ratio vs Industry

How does BIOC's PE Ratio compare vs other companies in the African Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.9%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.9%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: BIOC is expensive based on its Price-To-Earnings Ratio (35.3x) compared to the African Pharmaceuticals industry average (9.9x).


Price to Earnings Ratio vs Fair Ratio

What is BIOC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIOC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio35.3x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BIOC's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.